INCY · Incyte

S&P 500 #400 · Nasdaq

Risiko 5/10 · Specialty Biopharma · $129.93 ▲ 9.30%

Kennzahlen

• Price $129.93
• Market cap $26.0B
• P/E (ttm) 18.35
• Div yield none
• 52-wk range $71.00 – $132.58
• Index rank #400 / —

Wichtigste Risiken

• Jakafi (ruxolitinib) patent expiry approach (Primary revenue generator faces biosimilar cliff) — HIGH
• Clinical pipeline failure risk (Binary outcomes on mid-stage trials) — MED
• Vega Therapeutics $1.25B acquisition execution (Hematology portfolio integration risk) — MED
• Near 52w high after 70% YTD gain (Limited near-term catalyst visibility) — MED

Fazit

JAK inhibitor oncology specialist riding a 70% YTD surge on Opzelura's European expansion and hematology pipeline growth.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.